Major Players in the South Korea Ankylosing Spondylitis Market | Top Companies 2026

Major Players in the South Korea Ankylosing Spondylitis Market

The South Korea Ankylosing Spondylitis Market is defined by established pharmaceutical companies offering innovative biologics and biosimilars. Key players contributing to the market include Celltrion Inc., Samsung Bioepis Co., Ltd., Novartis Korea, and AbbVie Korea.

South Korea Ankylosing Spondylitis Market Overview

According to 6Wresearch, the market for ankylosing spondylitis in South Korea is currently undergoing tremendous growth, due to the increasing prevalence of the condition and the growing need for effective treatment solutions. Ankylosing Spondylitis is a chronic inflammatory disease that affects the spine and other joints. Today, the market is driven by the growing trend of using biologics and biosimilars, which offer patients effective solutions. In addition, various initiatives have been put in place by the government to ensure improved healthcare services and expanded universal health coverage.

Competitive Landscape

The competitive landscape of the South Korea ankylosing spondylitis Industry encompasses several global and domestic manufacturers, especially in the biologics and biosimilars sectors. The market position of the dominant companies in the market is sustained with continued investment in R&D, which helps in the development of innovative drugs, thus catering to the growing need for effective ankylosing spondylitis drugs.

Below is a list of leading players operating in the South Korea Ankylosing Spondylitis Market:

1. Celltrion, Inc.

Celltrion is a global leader in biosimilars, known for its Remsima brand, which is widely prescribed for ankylosing spondylitis patients.

2. Samsung Bioepis Co., Ltd.

Samsung Bioepis provides high-quality alternatives like Brenzys and Adalloce to the domestic market.

3. Novartis Korea

Novartis leads with innovative inhibitors like Cosentyx, which have become a standard of care for patients unresponsive to traditional TNF blockers.

4. AbbVie Korea

AbbVie remains a dominant force with Humira and its newer inhibitor portfolio, catering to a large patient base requiring advanced systemic therapy.

5. Yuhan Corporation

Yuhan is one of Korea's most trusted pharmaceutical brands, providing a wide range of anti-inflammatory maintenance drugs.

6. Hanmi Pharmaceutical Co., Ltd.

Hanmi is recognized for its advanced R&D and specialized formulations that support the chronic management of rheumatic diseases.

7. LG Chem, Ltd. (Life Sciences)

LG Chem’s Life Sciences division produces Etacept, a domestically developed biologic used extensively for treating spinal inflammation.

8. GC Biopharma (formerly Green Cross)

GC Biopharma focuses on immunology and protein-based therapies, contributing to the broader landscape of autoimmune care.

9. Daewoong Pharmaceutical Co., Ltd.

Daewoong maintains a strong presence through a robust distribution network and its own portfolio of pain management and anti-rheumatic solutions.

10. Chong Kun Dang Pharmaceutical Corp.

Chong Kun Dang is a key player in the development of biosimilars and second-line therapies for chronic inflammatory conditions.

Major Players in the South Korea Ankylosing Spondylitis Market: FAQs